Type of information: Clinical research agreement
Compound: NOX-A12 (olaptesed pegol) and Keytruda® (pembrolizumab)
Company: Noxxon Pharma (Germany) National Center for Tumor Diseases (NCT) in Heidelberg (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: clinical research
Disease: metastatic pancreatic cancer, metastatic colorectal cancer
Details: • On May 16, 2017 , Noxxon announced the signing of an agreement with the National Center for Tumor Diseases (NCT) in Heidelberg under which the NCT will conduct a trial evaluating Noxxon’s lead product candidate NOX-A12 in combination with Keytruda® (pembrolizumab) in metastatic pancreatic and colorectal cancer. In some preclinical studies, NOX-A12 has shown an ability to make the immediate area surrounding a model tumor, the so-called tumor microenvironment, more accessible to the immune system. The ability of many tumors to use the tumor microenvironment to hide from the immune system is believed to contribute to the insensitivity of some tumors towards checkpoint inhibitors, such as Keytruda®. The NCT investigators leading the clinical trial include Prof. Dr. Dirk Jäger, Managing Director, head of the clinical and tumor immunology research groups, and Dr. Niels Halama, Group Leader.